2019Champ is diagnosed at twelve. An aggressive perianal cancer had already been operated on and had come back, chemotherapy and radiation were ruled out as too much for him, and the vet mentioned that he had heard good things about CBD. In India she found no quality standard, no clinical testing, and a woman selling it somewhere in Delhi.
Nov 2019A bottle from Amsterdam, then the third of the month. A friend travelling there brought back a pet CBD product; the dog stopped whimpering through the night and began eating again, and died a few weeks later. She had a purpose by then and no idea how, when or what.
2021Awshad starts in a pandemic. Her co-founder was moving to America and got stuck in India, she was finished with a corporate career of more than a decade, and they pooled what they had. The licence is AYUSH, under which vijaya has been permitted all along.
2023Cordyceps arrives beside the CBD. The year's launch is a mushroom capsule built on the fungus Chinese Olympic athletes used where steroids were barred, meant to add vitality through the day to what the oil does for calm.
TodayThe category has to buy its credibility. Every batch goes to a laboratory in Florida for a certificate of analysis published for patients and doctors, ten doctors are bookable free inside the checkout because the edibles need a prescription, and about 80% of sales run through the company's own site since prescription gating closes Amazon.
Next yearBootstrapped, until it is not. They stayed self-funded on purpose, for agency and to build the value first, and expect to open to investors and push harder into physical pharmacies. The industry association is lobbying for rules that would let them use the word cannabis in an advertisement.
